SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 106.00+0.8%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Biotech Jim6/13/2013 7:36:59 AM
  Read Replies (1) of 3202
 
LLY and INCY report on Baricitinib efficacy and safety data from the open-label, lont-Term extension of the phase 2b JADA study in patients with RA:

investor.incyte.com

The data look pretty darn good to me, and similar to past results reported. Here is some of the reported data:

Disease
Improvement /
Activity Measure

24-Week

Responders/Total
Patients (Percent
Responders)

52-Week

Responders/Total
Patients (Percent
Responders)

ACR20

149/201 (74%)

139/196 (71%)

ACR50

83/201 (41%)

96/197 (49%)

ACR70

43/201 (21%)

53/197 (27%)

CDAI Remission

34/200 (17%)

40/195 (21%)

SDAI Remission

30/195 (15%)

42/194 (22%)

DAS28 ESR <2.6

35/200 (18%)

47/195 (24%)

DAS28 ESR </= 3.2

55/200 (28%)

82/195 (42%)

DAS28 CRP <2.6

59/195 (30%)

80/194 (41%)

DAS28 CRP </= 3.2

93/195 (48%)

116/194 (60%)

Boolean Remission

19/195 (10%)

32/194 (16%)

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News